Resistant Gram-Negative Bacilli ESBLs and Other Bad Bugs David P. Dooley, FACP UTHSC-San Antonio Audie Murphy VA Hospital San Antonio, TX.

Slides:



Advertisements
Similar presentations
TREATMENT FOR SUPERIMPOSED PSEUDOMONAS AERUGINOSA INFECTION.
Advertisements

East Texas Medical Center – Tyler Annual Physician Education MDRO -Multidrug-Resistant Organisms- Revised: April 2013.
ACT 52 - Healthcare-Associated Infections
Antimicrobial Resistance in Hospitals: Lack of Effective Treatment for Gram Negative Bacilli and the Rise of Resistant Clostridium difficile Infections.
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal
1 Benoît GUERY Infectious Diseases CHRU Lille Antibiotic strategies How to treat Multi-drug-resistant Pseudomonas.
Antibiotic treatment choices for SBP Treviso 8 Giugno 2009 P. Angeli Dept. of Clinical and Experimental Medicine University of Padova.
The Increasing Public Health Exigency of Antimicrobial Resistance Alfred DeMaria, Jr., M.D. Massachusetts Department of Public Health.
Emerging Antimicrobial Resistance in Texas The new ESBLs.
2009 CLSI M100-S19 Update Nebraska Public Health Laboratory.
Enoch Omonge University of Nairobi
APIC Chapter 13 Journal Club April 15, 2015
BAD BUGS! Alfred DeMaria, Jr., M.D. Massachusetts Department of Public Health.
MRSA and VRE. MRSA  1974 – MRSA accounted for only 2% of total staph infections  1995 – MRSA accounted for 22% of total staph infections  2004 – MRSA.
Resistance to  -lactam antibiotics within the Enterobacteriaceae Paul D. Fey, Ph. D. University of Nebraska Medical Center.
Preventing Multidrug-Resistant Organisms (MDROs) What the Direct Caregiver Should Know Prepared by: Ann Bailey, RNC, BSN, CIC Joanne Dixon, RN, MN, CIC.
Standard and Expanded Precautions
COL Helen Viscount, PhD, D(ABMM) LTC Steven Mahlen, PhD, D(ABMM)
CHOICE OF ANTIBIOTICS IN THE VIEW OF DEVELOPING ANTIBIOTIC RESISTANCE Dr. Jolanta Miciulevičienė Vilnius City Clinical Hospital National Public Health.
Multidrug-Resistant Bacteria in Solid Organ Transplantation Jordi Carratalà Department of Infectious Diseases IDIBELL-Hospital Universitari de Bellvitge.
NOSOCOMIAL INFECTIONS Phase 1: Testing the efficacy of Nano-Mg (OH) 2 Dorothea A. Dillman PhD, RN, CCRN, LNC.
Train-the-Trainer Understanding multidrug-resistance: Focus on Carbapenems Customize this presentation with your organization’s logo, etc. 13/17/2014.
CSI 101 Skills Lab 2 Standard Precautions Personal Protective Equipment (PPE) Daryl P. Lofaso, M.Ed, RRT.
Nosocomial infection Hospital Infection. Hospital acquired infections Nosocomial infections are those that originate or occur in a hospital or hospital-like.
Methicillin-resistant Staphylococcus Aureus - MRSA - Sharon Walker, RN, BPS Ingham County Health Department.
ANTIMICROBIAL RESISTANCE
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 83 Basic Principles of Antimicrobial Therapy.
SPM 100 Clinical Skills Lab 1 Standard Precautions Sterile Technique Daryl P. Lofaso, M.Ed, RRT.
Division of Public Health CRE Surveillance and Prevention of Transmission in Healthcare Settings Gwen Borlaug, CIC, MPH Coordinator, Healthcare-Associated.
Time To Regain Control Management of Multi-Drug Resistant Organisms in Healthcare Settings
Antimicrobial Resistance patterns among nosocomial gram negative bacilli by E-test and disc diffusion methods in Sina and Imam Hospital.
SPM 100 Skills Lab 1 Standard Precautions Sterile Technique Daryl P. Lofaso, M.Ed, RRT Clinical Skills Lab Coordinator.
Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.
Bacterial Resistance in China
Empirical Therapy for Ventilation Associated Pneumonia Azar. Hadadi Associate Professor of Infectious Diseases.
Outlines At the completion of this lecture the student will be able to identify the concept and related terms of: Infection- Infection control-
INTRODUCTION TO INFECTION CONTROL ICNO Infection Control Unit, Teaching Hospital, Jaffna.
European Centre for Disease Prevention and Control
MICROBIOLOGICAL EPIDEMIOLOGY OF RESPIRATORY SPECIMENS IN ICU PATIENTS Dr Farooq Cheema, Dr Waseem Tariq, Dr Raja Ishtiaq, Dr Tabassum Qureshi, Dr Vincent.
Országos Epidemiológiai Központ National Center for Epidemiology, Budapest, Hungary Activities in Hungary for preventing AMR and controlling HCAI Emese.
KJO Hospital Infection Control Local 2176/2097 Ross Ibabao/ICCo.
Guideline for the Diagnosis and Management of Adults in LTC with Urinary Tract Infection (Part 2) This is intended as a guide for evidence-based decision-making.
Epidemiology of Hospital Acquired Infections By Alena Bosconi, Candice Smith, Dusica Goralewski SUNY Delhi Biol , Infection and Disease Dr. Marsha.
Nosocomial Infections Emergence of Antimicrobial Resistance Mazen Kherallah, MD, FCCP King Faisal Specialist Hospital & Research Center.
Strategies in the Selection of Antibiotic Therapy in the ICU Mazen Kherallah, MD, FCCP King Faisal Specialist Hospital & Research Center.
Part II High Priority Resistant Organisms. Healthcare Associated Infections NHSN Staphylococcus aureus (16%) 2.Enterococcus spp (14%) 3.Escherichia.
Multi-Resistant Gram Negative Microorganisms St Elisabeth Hospital Curacao.
1 A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital DIABETES Care; Aug 2006; 29,8 : FM R1 임혜원.
(Ambler class A, Bush group 2) Inhibited by CA
Anton Y. Peleg, M.B., B.S., M.P.H., and David C. Hooper, M.D. N Engl J Med 2010;362: Hospital-Acquired Infections Due to Gram-Negative Bacteria.
Acinetobacter Before we begin the investigation, we must prepare for field work. The preparation requires that we learn about the organism involved in.
Outcomes of Carbapenem-Resistant K. pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies Gopi Patel, MD; Shirish Huprikar, MD;
HAP and VAP Guidelines Update
Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae
Antibiotics: handle with care!
Current Status of Antimicrobial Resistance
N°XXXX Rapid detection of extended-spectrum BETA-lactamase producing Enterobacteriaceae from urine using the ESBL NDP test Patrice Nordmann, Laurent Poirel,
The Role of the Microbiology Laboratory in AMS programs
Antibiotic Resistance
Antibiotics: handle with care!
Antimicrobial Resistance in Hospitals: Lack of Effective Treatment for Gram Negative Bacilli and the Rise of Resistant Clostridium difficile Infections.
Antibiotics sensitivity of microorganism causing nosocomial infections
Before an outbreak - what to do after first MDR Gram-negatives enter your hospital? Jon Otter, PhD FRCPath Imperial College London
Neonatal sepsis in Kilifi
CPE: coming to a hospital near you!
C th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, Washington, DC Examining Temocillin Activity in Combination.
“Bug of the month “ Pseudomonas aeruginosa (Gram negative bacilli)
TRAINING PRESENTATION
Antibiotics: handle with care!
Fighting MDR G-Negative Infections
Presentation transcript:

Resistant Gram-Negative Bacilli ESBLs and Other Bad Bugs David P. Dooley, FACP UTHSC-San Antonio Audie Murphy VA Hospital San Antonio, TX

Resistant GNB The Problem Still common in their nichés; level prevalance of GNBs, but resistance rising

Results of intensive care unit surveillance revealing percentages of gram-positive (Gram Pos) and gram-negative (Gram Neg) pathogens associated with pneumonia, urinary tract infection (UTI), surgical site infection (SSI), and bloodstream infection (BSI)—National Nosocomial Infections Surveillance system, 1986–2003.

Results of intensive care unit surveillance for the proportion of selected gram-negative organisms reported for pneumonia from the National Nosocomial Infections Surveillance system, 1986–2003. Gaynes R CID 2005 (CDC)

Resistant GNRs Prevalence of isolates of multidrug-resistant gram-negative bacilli recovered within the first 48 h after admission to the hospital, by species. Only 1 isolate per patient per year was included in the study. Pop-Vicas, Clin Inf Dis 40: (MGH)

Results of intensive care unit surveillance revealing rates of antimicrobial resistance to third-generation cephalosporins among Klebsiella pneumoniae isolates (which includes isolates that were either intermediately susceptible or resistant) and Escherichia coli isolates—National Nosocomial Infections Surveillance system, 1986–2003. Gaynes R CID 2005 (CDC)

INCIDENCE RATES OF MULTIDRUG-RESISTANT BACTERIA PER 100 ADMISSIONS: STAPHYLOCOCCUS AUREUS (LINE WITH BLACK DIAMONDS), PSEUDOMONAS AERUGINOSA (LINE WITH WHITE DIAMONDS), ENTEROBACTERIACEAE (LINE WITH BLACK BOXES), AND ACINETOBACTER BAUMANNII (LINE WITH WHITE BOXES). Lepelletier D ICHE Nantes

Resistant GNB The Problem High mortality Narrowing therapeutic options –Down to carbapenems, polymixin B

New antibacterial agents approved in the United States, 1983–2002, per 5-year period. Spellberg B et al. Clin Inf Dis 2004

Resistant GNB The Problem Hard to detect: may be in your building for months/years before you get worried Not sexy; no media exposure –How to compete with alarms about MRSA?

Resistant GNB Organisms of concern: –Pseudomonas aeruginosa –Acinetobacter baumannii –Enterobacteriaceae: Klebsiella pneumoniae Enterobacter spp. (esp cloacae) E. coli Serratia marcescens

Hyle EP Arch Int Med 2005 (HUP) Sites of infection with extended-spectrum β-lactamase–producing Escherichia coli and Klebsiella species: 187 patients at HUP, over 5 y

Resistant GNB Clinical Significance High mortality, especially with pneumonia or BSIs Clear effect of delay in appropriate therapy on survival –40-100% mortality when treating apparently susceptible deep infections with Klebsiella with cephalosporins

Delay in initial antimicrobial therapy and mortality. Hyle EP Arch Int Med 2005 (HUP)

Resistant GNB Clinical Significance NNIS data –20% of ICU Klebsiella isolates are resistant to 3 0 cephalosporins –30% of ICU Enterobacter isolates similar –6% of E. coli isolates similar –(Netherlands: <1% of Klebsiella with ESBLs!)

Resistant GNB Epidemiology Risks for acquisition: No surprises –Current and previous abx Tx –Older patient (>60 y) –ICU stay; prolonged ICU stay –IV catheters; tubes of every kind –NH/LTCF denizen (1/2 colonized with ESBLs!) –H2 receptor blockers (Zantac et al) –Chronic liver/renal disease

Safdar N, Maki DG, Ann Int Med 2002;136:834

Resistant GNB Epidemiology Risk of deep infection >> if previously colonized (40 fold) 15% of colonized patients go on to invasive infection Rare “community-acquired”

Resistant GNB Epidemiology: when/how acquired? Horizontal transfer vs endogenous source –Unlike MRSA, VRE---overwhelmingly horizontal transfer –Endogenous: Enterobacteriaceae seldom spontaneously resistant; Pseudomonas not cultured from normal individuals (Acinetobacter +/-) But resistance in same clone emerges commonly under antibiotic pressure

Resistant GNB Epidemiology: when/how acquired? Clearly some horizontal transfer though How? –5% (<< MRSA) of area around bedside of colonized patients are colonized with resistant GNBs---but they’re there– environmental reservoir (Clearly documented point source outbreaks) –Large (undetermined) percentage of colonization occurs through HCWs hands (esp Klebsiella and Acinetobacter)

PERCENTAGE OF HAND IMPRINT CULTURES YIELDING PATHOGENS AFTER CONTACT WITH ENVIRONMENTAL SURFACES NEAR PATIENTS IN OCCUPIED PATIENT ROOMS OR IN ROOMS THAT HAD BEEN CLEANED AFTER PATIENT DISCHARGE. Bhalla A ICHE 2004 (Cleveland)

Larson EL et al Ped Crit Care Med 2005

Distribution of infant and nurse clones identified as unique strains, strains shared between nurses and infants, and strains shared between nurses or among infants. Waters V, Clin Inf Dis 2004 (Columbia)

Resistant GNB Basis of Resistance Pseudomonas aeruginosa, Acinetobacter spp. Intrinsically resistant through multiple mechanisms: –β-lactamases—many possible –Aminoglycoside modifying enzymes –Porin mutations, with abx exclusion –Efflux pumps up and running –Topoisomerases for FQs

Resistant GNB Basis of Resistance Enterobacteriaceae: β-lactamases rising –1960’s—routine enzymes (TEM 1, SHV 1): ampicillin, Keflex resistant –1980’s—mutations; “extended spectrum”— DNA encoded on plasmids, jump to other GNBs easily Active against 3 0 cephalosporins, aztreonam Not active (stay susceptible) against cefoxitin, cefotetan, and β-lactamase inhibitors (Zosyn, Augmentin, Unasyn) –Currently >100 ESBLs recognized

Resistant GNB Basis of Resistance: Example Klebsiella pneumoniae, old TEM 1: AmpR KeflexR CefoxitinS Cefotaxime/ceftriaxoneS CeftazidimeS CefipimeS ZosynS CiproS AminoglycosideS BactrimS

Resistant GNB Basis of Resistance: Example Klebsiella pneumoniae, old TEM 1; new ESBL: AmpRR KeflexRR CefoxitinSS Cefotaxime/ceftriaxoneSR CeftazidimeSR CefipimeS(S) ZosynSS CiproS(S) AminoglycosideS(S) BactrimS(S)

Resistant GNB Basis of Resistance Amp C β–lactamases: newer, broader R –Chromosomal: don’t jump so much –Mostly on Enterobacters; rare Kleb –Do cause R to cefoxitin, and β–lactamase inhibitor combinations

Resistant GNB Basis of Resistance: Example Klebsiella pneumoniae, old TEM 1; new ESBL; Amp-C AmpRRR KeflexRRR CefoxitinSSR Cefotaxime/ceftriaxoneSRR CeftazidimeSRR CefipimeS(S)(S) ZosynSSR CiproS(S)(S) AminoglycosideS(S)(S) BactrimS(S)(S)

Resistant GNB Basis of Resistance ESBLs and Amp-C β–lactamases are inoculum dependent –Usual tests are at low inoculum; may look S –In vivo, high loads of bugs common; clinical failures of the “S” abx is common Requires special testing techniques –If not performed, ESBL/Amp-C bugs may look S but your patients are dying –CLSI recommends specific testing; if ESBL or Amp C are found, trust NO and treat with NO β-lactam except carbapenem (imipenem, meropenem, ertapenem)

Resistant GNB Deceptive Susceptibility Testing: ESBLs May Look Sensitive Klebsiella pneumoniae AmpR KeflexR CefoxitinS Cefotaxime/ceftriaxoneS Ceftazidime(S) CefipimeS ZosynS CiproS AminoglycosideS BactrimS

Resistant GNB Deceptive Susceptibility Testing: Amp-C’s May Look Sensitive Early On Enterobacter spp. Amp-C early Amp C 3-10 d later AmpRR KeflexRR CefoxitinSR Cefotaxime/ceftriaxoneSR CeftazidimeSR CefipimeS(S) ZosynSR Cipro(S)(S) Aminoglycoside(S)(S) Bactrim(S)(S)

Double-disk susceptibility test for ESBLs, this time in Enterobacter cloacae. AMC (center) = clavulanic acid; FEP = cefepime; CAZ = ceftazidime; CXT = cefotaxime; CRO = ceftriaxone

Resistant GNB Treatment Must pick adequate coverage immediately (reviewed already). –Greater survival differences in under-treated resistant GNBs than even under-treated MRSA –Patients at risk should receive broader coverage –Carbapenems; +/- double GNB coverage

Rahal et al Clin Inf Dis 2002;34:501 “Squeezing the balloon”. Evolution and control of antibiotic resistance among gram-negative bacilli at New York Hospital Queens. ICU, intensive care unit.

Resistant GNB Infection Control Issues Prevention of transmission of resistant Staphylococcus aureus and Enterococcus specifically addressed in 2003 SHEA guideline* –Call for active surveillance cultures, based on Recognition that colonization precedes infection Response with barrier precautions works to reduce clinical infections Response if wait till clinical cultures return positive is less impressive (vs no help) * Muto CA ICHE 2003;24:362

Resistant GNB Infection Control Issues HICPAC guidelines address all MDROs* Call for measured response: Active surveillance (rectal cultures in case of ESBLs) if institution “has a problem” Otherwise, adjust level of surveillance/recognition to overall need, or focus on geographic areas in house (e.g., ICUs) Decisions made on basis of your institution’s amount of problem, resources, administration’s interest † * Siegel et al † Discussion at Jackson M et al AJIC 2004;32:504

Resistant GNB Infection Control Issues Other components of infection control: –Antibiotic stewardship program* Probably as or more important here than for other MDRO’s Carbapenems for empirical therapy; avoid ceftazidime; avoid 3 0 cephalosporins in general (Zosyn maybe helfpul) –Contact precautions*: interrupt environmental risk Determine clonality if available (also, ? Point source?) * Good evidence intervention works

Resistant GNB Infection Control Issues –Hand hygiene* –Cohorting patients*, cohorting staff* –Good staffing ratios* * Good evidence intervention works

Resistant GNB Infection Control Issues Cautions: –Contact precaution data is not usually in isolation –Active surveillance costs: Money Time Effort